Drug Shortage Report for RAPAFLO
| Report ID | 56121 |
| Drug Identification Number | 02361663 |
| Brand name | RAPAFLO |
| Common or Proper name | Rapaflo |
| Company Name | ALLERGAN INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | SILODOSIN |
| Strength(s) | 4MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL |
| Packaging size | 30 cap bottle |
| ATC code | G04CA |
| ATC description | DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | |
| Actual start date | 2018-07-06 |
| Estimated end date | 2018-08-10 |
| Actual end date | 2018-09-03 |
| Shortage status | Resolved |
| Updated date | 2018-09-25 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Company contact information; Telephone number: 800-668-6424 Email address: MR-GENERAL_INQUIRY@allergan.com Website address: allergan.ca Postal address: 500-85 Enterprise Blvd, Markham, Ontario, L6G 0B5 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2018-09-25 | French | Compare |
| v3 | 2018-09-25 | English | Compare |
| v2 | 2018-07-20 | French | Compare |
| v1 | 2018-07-20 | English | Compare |
Showing 1 to 4 of 4